Nanotechnology and Parkinson’s disease

Mavridis, Ioannis N.; Meliou, Maria; Pyrgelis, Efstratios-Stylianos; Agapiou, Eleni

doi:10.1016/b978-0-12-813667-6.00001-2

Cited by 7 publications

(5 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 28 Owing to BBB restrictions, current drug delivery to the brain cannot restore or maintain the cytoarchitecture acceptably. 29 Numerous nanodelivery systems, such as nano-phytobioactive substances, have shown promise in PD treatment. The use of solid lipid NPs, nanolipid carriers, and nanoliposomes has further enhanced the permeability, solubility, and stability of substances for delivery to the target region.…”

Section: Parkinson’s Diseasementioning

confidence: 99%

See 1 more Smart Citation

How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature

Mohapatra,

Gopikrishnan,

Doss C

et al. 2024

IJN

View full text Add to dashboard Cite

New nanotechnology strategies for enhancing drug delivery in brain disorders have recently received increasing attention from drug designers. The treatment of neurological conditions, including brain tumors, stroke, Parkinson’s Disease (PD), and Alzheimer’s disease (AD), may be greatly influenced by nanotechnology. Numerous studies on neurodegeneration have demonstrated the effective application of nanomaterials in the treatment of brain illnesses. Nanocarriers (NCs) have made it easier to deliver drugs precisely to where they are needed. Thus, the most effective use of nanomaterials is in the treatment of various brain diseases, as this amplifies the overall impact of medication and emphasizes the significance of nanotherapeutics through gene therapy, enzyme replacement therapy, and blood-barrier mechanisms. Recent advances in nanotechnology have led to the development of multifunctional nanotherapeutic agents, a promising treatment for brain disorders. This novel method reduces the side effects and improves treatment outcomes. This review critically assesses efficient nano-based systems in light of obstacles and outstanding achievements. Nanocarriers that transfer medications across the blood-brain barrier and nano-assisted therapies, including nano-immunotherapy, nano-gene therapy, nano enzyme replacement therapy, scaffolds, and 3D to 6D printing, have been widely explored for the treatment of brain disorders. This study aimed to evaluate existing literature regarding the use of nanotechnology in the development of drug delivery systems that can penetrate the blood-brain barrier (BBB) and deliver therapeutic agents to treat various brain disorders.

show abstract

Section: Parkinson’s Diseasementioning

confidence: 99%

Section: Parkinson's Diseasementioning

confidence: 99%

How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature

Mohapatra,

Gopikrishnan,

Doss C

et al. 2024

IJN

View full text Add to dashboard Cite

show abstract

“…The various IN and systemic nanotechnologies that have been leveraged to treat PD have been extensively reviewed, − so only a few studies will be reiterated here. A nanoparticle employing non-Fe hemin as the iron chelator and protected by a zwitterionic species was conjugated to HIV-1 trans-activating transcriptor (TAT) to promote delivery across the BBB .…”

Section: In Nanoformulations Of Dfomentioning

confidence: 99%

Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer’s Disease, Parkinson’s Disease, and Intracerebral Hemorrhage

Farr

Xiong

2020

Mol. Pharmaceutics

View full text Add to dashboard Cite

Deferoxamine mesylate (DFO) is an FDA-approved, hexadentate iron chelator routinely used to alleviate systemic iron burden in thalassemia major and sickle cell patients. Iron accumulation in these disease states results from the repeated blood transfusions required to manage these conditions. Iron accumulation has also been implicated in the pathogenesis of Alzheimer’s disease (AD), Parkinson’s disease (PD), and secondary injury following intracerebral hemorrhage (ICH). Chelation of brain iron is thus a promising therapeutic strategy for improving behavioral outcomes and slowing neurodegeneration in the aforementioned disease states, though the effectiveness of DFO treatment is limited on several accounts. Systemically administered DFO results in nonspecific toxicity at high doses, and the drug’s short half-life leads to low patient compliance. Mixed reports of DFO’s ability to cross the blood–brain barrier (BBB) also appear in literature. These limitations necessitate novel DFO formulations prior to the drug’s widespread use in managing neurodegeneration. Herein, we discuss the various dosing regimens and formulations employed in intranasal (IN) or systemic DFO treatment, as well as the physiological and behavioral outcomes observed in animal models of AD, PD, and ICH. The clinical progress of chelation therapy with DFO in managing neurodegeneration is also evaluated. Finally, the elimination of intranasally administered particles via the glymphatic system and efflux transporters is discussed. Abundant preclinical evidence suggests that intranasal DFO treatment improves memory retention and behavioral outcome in rodent models of AD, PD, and ICH. Several other biochemical and physiological metrics, such as tau phosphorylation, the survival of tyrosine hydroxylase-positive neurons, and infarct volume, are also positively affected by intranasal DFO treatment. However, dosing regimens are inconsistent across studies, and little is known about brain DFO concentration following treatment. Systemic DFO treatment yields similar results, and some complex formulations have been developed to improve permeability across the BBB. However, despite the success in preclinical models, clinical translation is limited with most clinical evidence investigating DFO treatment in ICH patients, where high-dose treatment has proven dangerous and dosing regimens are not consistent across studies. DFO is a strong drug candidate for managing neurodegeneration in the aging population, but before it can be routinely implemented as a therapeutic agent, dosing regimens must be standardized, and brain DFO content following drug administration must be understood and controlled via novel formulations.

show abstract

“…• Otros síntomas: aunque es poco frecuente pueden presentarse sangrados intratumorales (cuadro llamado apoplejía pineal, con hemorragia subaracnoidea y/o hemorragia intraventricular), hipertermia, convulsiones y tinitus, como manifestaciones más frecuentes. 5 El método diagnóstico de elección es la resonancia magnética con contraste. Las características imagenológicas dependen del tipo de lesión pineal.…”

Section: Introductionunclassified

“…El objetivo de este trabajo es proponer una clasificación por grupo de pacientes y un algoritmo de manejo para los pacientes con lesiones pineales. 5,6 Grupos de pacientes Cuando una imagen diagnóstica evidencia una lesión pineal podemos encontrar diferentes grupos de pacientes, los cuales tendrán diferente tratamiento y seguimiento. De esta manera encontramos: • Grupo 1a: Pacientes asintomáticos con lesiones pineales de aspecto quístico (incidentalomas).…”

Section: Introductionunclassified